305 related articles for article (PubMed ID: 36077691)
1. HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies.
Uy NF; Merkhofer CM; Baik CS
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077691
[TBL] [Abstract][Full Text] [Related]
2. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
Riudavets M; Sullivan I; Abdayem P; Planchard D
ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
[TBL] [Abstract][Full Text] [Related]
3. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.
Yu Y; Yang Y; Li H; Fan Y
Cancer Treat Rev; 2023 Mar; 114():102520. PubMed ID: 36738637
[TBL] [Abstract][Full Text] [Related]
4. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC.
Baraibar I; Mezquita L; Gil-Bazo I; Planchard D
Crit Rev Oncol Hematol; 2020 Apr; 148():102906. PubMed ID: 32109716
[TBL] [Abstract][Full Text] [Related]
5. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
[TBL] [Abstract][Full Text] [Related]
6. Consensus for HER2 alterations testing in non-small-cell lung cancer.
Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Genomic Features of
Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
[TBL] [Abstract][Full Text] [Related]
8. A narrative review of antibody-drug conjugates in
Hsu R; Benjamin DJ
Front Oncol; 2023; 13():1252652. PubMed ID: 38107063
[TBL] [Abstract][Full Text] [Related]
9.
Sentana-Lledo D; Academia E; Viray H; Rangachari D; Kobayashi SS; VanderLaan PA; Costa DB
Transl Lung Cancer Res; 2023 Jul; 12(7):1590-1610. PubMed ID: 37577308
[TBL] [Abstract][Full Text] [Related]
10. Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).
Gaye E; Penel N; Lebellec L
Curr Opin Oncol; 2022 Sep; 34(5):570-574. PubMed ID: 35943440
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
Takakura T; Yamamoto N
Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
[TBL] [Abstract][Full Text] [Related]
12. Advanced non-small-cell lung cancer: how to manage
Metro G; De Giglio A; Ricciuti B; Siringo M; Marinelli D; Gelibter A; Pecci F; Berardi R; Cantini L; Di Federico A; Andrini E; Mosca M; Lamberti G; Brambilla M; Mountzios G
Drugs Context; 2022; 11():. PubMed ID: 35975031
[No Abstract] [Full Text] [Related]
13. HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches.
Garrido-Castro AC; Felip E
Transl Lung Cancer Res; 2013 Apr; 2(2):122-7. PubMed ID: 25806223
[TBL] [Abstract][Full Text] [Related]
14. Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review.
Metro G; Baglivo S; Moretti R; Bellezza G; Sidoni A; Roila F
Oncol Ther; 2020 Dec; 8(2):341-350. PubMed ID: 32700047
[TBL] [Abstract][Full Text] [Related]
15. Targeting HER2 Alterations in Non-Small-Cell Lung Cancer: A Comprehensive Review.
Zhao J; Xia Y
JCO Precis Oncol; 2020 Nov; 4():411-425. PubMed ID: 35050738
[TBL] [Abstract][Full Text] [Related]
16. Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations.
Ni J; Zhang L
Onco Targets Ther; 2021; 14():4087-4098. PubMed ID: 34262294
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
18. NSCLC and HER2: between lights and shadows.
Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
[TBL] [Abstract][Full Text] [Related]
19. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Impact of
Bontoux C; Benzaquen J; Hofman V; Heeke S; Hannetel P; Capela-Brosseau-Laborde P; Marquette CH; Ilié M; Hofman P
J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
